Skip to content
Twitter page opens in new windowLinkedin page opens in new windowInstagram page opens in new windowYouTube page opens in new window
[email protected]+61 3 9692 7222
PharmAust (PAA)
Cancer Therapeutics Research
PharmAust (PAA)
  • HOME
  • ABOUT
    • Board
    • Management
    • Corporate Directory
  • PIPELINES & TRIALS
    • Monepantel for Motor Neurone Disease
    • Publications
  • INVESTOR HUB
    • ASX Announcements
    • Annual Reports
    • Investor Presentations
    • Analyst Reports
    • Financial Reports
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Videos
    • Media
  • CONTACT
  • HOME
  • ABOUT
    • Board
    • Management
    • Corporate Directory
  • PIPELINES & TRIALS
    • Monepantel for Motor Neurone Disease
    • Publications
  • INVESTOR HUB
    • ASX Announcements
    • Annual Reports
    • Investor Presentations
    • Analyst Reports
    • Financial Reports
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Videos
    • Media
  • CONTACT

Author Archives: PharmAust

PharmAust anti-cancer agent six times more effective

Articles In The NewsBy PharmAust24/11/2017

PharmAust Identifies New Proprietary Monepantel-related Compounds With Greater Anti-cancer Activity

News & Announcements 2017By PharmAust23/11/2017

171123_Improved potency of MPL analogues_clean

PharmAust locks down US patent for cancer drugs

Articles In The NewsBy PharmAust17/11/2017

PharmAust secures patent in US for new portfolio of anticancer drugs

News & Announcements 2017By PharmAust16/11/2017

17113_MPL4_US_New drugs patented for cancer_(clean)

Dogs needed to help evaluate a promising new anti-cancer drug

News & Announcements 2017, Press ReleaseBy PharmAust13/11/2017

New cancer treatment available for dogs with lymphoma

PharmAust subsidiary Epichem named WA exporter of the year

Articles In The NewsBy PharmAust02/11/2017

Epichem Update

News & Announcements 2017By PharmAust01/11/2017

171101_Epichem Update

AGM notice

Financial Reports 2017, News & Announcements 2017By PharmAust01/11/2017

171027_AGM notice

PharmAust achieves key goal with anti-cancer drug

Articles In The NewsBy PharmAust18/10/2017

Monepantel reformulation project continues to progress

News & Announcements 2017By PharmAust17/10/2017

171017_Monepantel reformulation project continues to progress

←1
23456789101112131415161718192021222324252627282930313233
…3435363738…
39404142434445464748495051
52→
MENU
  • Home
  • About Us
  • Pipeline & Trials
  • Investor Centre
  • Media
  • Contact Us
SUBSCRIBE TO OUR NEWSLETTER

PharmAust Follow

PharmAust is a clinical-stage biotech company focused on repurposing monepantel (MPL) for human neurodegenerative diseases ASX: $PAA FSE: $ECQ

PharmAust
pharmaust PharmAust @pharmaust ·
24 Jun

📸 Highlights from the MND Australia Global Day Event at Parliament House!

We teamed up with FightMND to raise awareness and fight for a future free of Motor Neurone Disease. 💙

#MNDAustralia #FightMND #MNDGlobalDay

Reply on Twitter 1805134834358210569 Retweet on Twitter 1805134834358210569 2 Like on Twitter 1805134834358210569 12 Twitter 1805134834358210569
Retweet on Twitter PharmAust Retweeted
stockheadau Stockhead @stockheadau ·
21 Jun

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.
#ASX @PharmAust

Reply on Twitter 1803984607676654065 Retweet on Twitter 1803984607676654065 1 Like on Twitter 1803984607676654065 3 Twitter 1803984607676654065
pharmaust PharmAust @pharmaust ·
21 Jun

Exciting news for our investors! 🎉 Check out the details of our latest capital raise here: https://investorhub.pharmaust.com/investment-offer/32. Thank you for your continued support! 🌟 #PharmAust

Reply on Twitter 1804030728956711230 Retweet on Twitter 1804030728956711230 2 Like on Twitter 1804030728956711230 7 Twitter 1804030728956711230
Load More

Copyright © 2024 PharmAust. All rights reserved.
nil

Website Design & Digital Marketing Perth by Total Click Solutions

Go to Top